Advertisement

If you’d invested in: Dechra Pharmaceuticals and Shire

Dechra Pharmaceuticals is a drugs company that specialises in the development of medical treatments for pets. Over the next three years, the firm’s earnings per share is expected to more than double. 

If only...

873_Good

Dechra Pharmaceuticals (LSE: DPH) is a drugs company that specialises in the development of medical treatments for pets. Pet ownership is on the rise around the globe, as is spending on those pets, so Dechra is operating in a booming market.

Over the next three years, the firm's earnings per share is expected to more than double. Over the same time period, revenue is predicted to grow from £359m to £465m; profit, from £26m to £57m.

Be glad you didn't

873_Bad

Shire (LSE: SHP) is a biotechnology group with treatments for attention-deficit hyperactivity disorder and inflammatory bowel disease, among others. It has suffered from problems in the production of one of its best-selling drugs, Cinryze. Despite this, the firm has posted a 7% rise in sales to £3.7bn in the quarter to the end of September. Management is considering splitting the firm in two so it can focus more on developing medicines for rare diseases.

Advertisement
Advertisement

Recommended

Visit/investments/stocks-and-shares/share-tips/600641/share-tips-of-the-week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Visit/520181/how-the-fear-of-death-affects-your-investment-process
Investment strategy

How the fear of death affects our investment processes

Many of our investment decisions are driven by one simple fact: the knowledge that, one day, we will be dead. Here, in an extract from his new book, J…
2 Jan 2020
Visit/519913/share-tips-8-stocks-for-robust-returns
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019
Visit/520060/the-good-and-the-bad-investments-of-2010s
Stockmarkets

The good investments of the 2010s – and the bad

John Stepek takes a look back on which investments did well and which did badly in the decade that’s about to come to an end.
26 Dec 2019

Most Popular

Visit/economy/global-economy/601420/james-ferguson-the-virus-the-lockdown-and-what-comes-next
Global Economy

The MoneyWeek Podcast: James Ferguson on the virus, the lockdown, and what comes next

Merryn talks to MoneyWeek regular James Ferguson of Macrostrategy Partnership about what's happened so far with the virus; whether the lockdown was th…
28 May 2020
Visit/economy/uk-economy/601427/covid-bounce-back-loans-and-inflation
UK Economy

What bounce back loans can tell us about how we’ll pay for all this

The government will guarantee emergency "bounce back loans" for small businesses hit by Covid-19. Inevitably, many businesses will default. And there'…
1 Jun 2020
Visit/investments/stockmarkets/601423/as-full-lockdown-ends-what-are-the-risks-for-investors
Stockmarkets

As full lockdown ends, what are the risks for investors?

In the UK and elsewhere, people are gradually being let off the leash as the lockdown begins to end. John Stepek looks at what risks remain for invest…
29 May 2020